Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint
preservation company in early intervention orthopedics, today
reported financial results for its second quarter ended June 30,
2024.
Second Quarter 2024 Financial Summary (compared
to the second quarter of 2023)
- Revenue $41.9 million, decreased 5%
- OA Pain Management revenue $26.7 million, decreased 9%
- Joint Preservation and Restoration revenue $13.5 million,
increased 7%
- Non-Orthopedic revenue $1.7 million, decreased 26%
- Gross margin 65%; Adjusted gross margin1 66%
- Net loss ($0.1) million, ($0.01) per share
- Adjusted net income1 $2.5 million, $0.17 per diluted share
- Adjusted EBITDA1 $6.3 million
- Cash used for operating activities $1.1 million
- Cash balance $62.8 million
1 See description of non-GAAP financial information contained in
this release.
“We are pleased with our financial performance in Q2 as we made
meaningful progress on our re-focused business strategy and path to
profitability,” commented Cheryl R. Blanchard, Ph.D., Anika’s
President and CEO. “In July, as planned, we announced the full
market release of our Integrity Implant System. This marks an
important step in the continued expansion of our differentiated
Regenerative Solutions portfolio. In the first half of 2024 during
the limited market release, we completed more than double the
number of cases than initially anticipated, demonstrating the
significant surgeon pull for this transformational product.
Integrity will be a true game changer for the future of rotator
cuff and other tendon repairs. Our HA-based Regenerative Solutions
portfolio, including Integrity, represents a key enabler for
Anika’s growth as we prepare for the US launch of Hyalofast by 2026
and file the first PMA module this year.”
Dr. Blanchard continued, “OA Pain Management remains a strong,
foundational element of our business and represents a key aspect of
total company profitability. Outside the US, Cingal, together with
Monovisc and Orthovisc, grew 17% in the first half of 2024 as we
gained market share and expanded into new countries. In the US, we
continue to drive progress towards Cingal’s FDA approval. In
addition, we continue to hold the market-leading position in the US
with both Monovisc and Orthovisc, despite softer pricing dynamics
as our US sales and marketing partner works to improve market
access.”
“In 2024, we have re-focused our business strategy to accelerate
profitability and deploy capital towards our highest returning
programs, while also continuing to explore strategic alternatives
to generate shareholder value. We announced a new $40 million share
repurchase program during the second quarter and executed cost
restructuring initiatives to enable investments into our highest
growth areas in OA Pain Management and Regenerative Solutions.
These actions focus our investments on the highest value building
opportunities and position Anika to maximize shareholder value in
the future.”
Strategic Updates
- Full Market Release of Integrity Implant System Expands
Growing Regenerative Solutions Portfolio
- Entered full market release of the Integrity Implant System, an
HA-based regenerative scaffold with arthroscopic instrumentation,
in July 2024, with over 300 successful cases completed by more than
60 surgeons in the shoulder and foot/ankle during limited market
release. Integrity will drive near-term growth for Anika’s
regenerative solutions portfolio and provides a platform to further
expand our regenerative HA offerings with new products that will
deliver long-term shareholder value.
- Remain on track to file the first Hyalofast modular PMA
submission in 2024 with the final clinical module filing expected
in 2025 to support the US product launch by 2026.
- Leadership in OA Pain Management Driven by
International Growth
- Grew international OA Pain Management revenue 17% in the first
half of 2024 with growth in all three brands of Cingal, Monovisc,
and Orthovisc driven by market share gains and new country
expansion.
- Maintained US market leadership with Monovisc and Orthovisc as
we work with the FDA to bring Cingal to the US market, doubling our
US OA Pain market opportunity to $2 billion.
- Executing on Re-focused Business Strategy and Enhancing
Capital Allocation
- Completed the previously announced cost reduction initiatives
to reduce expenses by $10 million annualized which has contributed
to the $8.8 million in year-to-date adjusted EBITDA, up 73%
compared to the same period in 2023.
- Announced a new $40 million stock repurchase program with $15
million being executed under a 10b5-1 plan initiated in May 2024
and to be completed by June 2025, with remainder to be executed in
open market purchases through June 2026.
Fiscal 2024 GuidanceAnika continues to expect
that revenue for fiscal 2024 will be in the range of $168 to $173
million, representing growth of 1% to 4% compared to 2023.
Revenue ranges by product family are:
- OA Pain Management of $102 to $104 million, up 0% to 2%
- Joint Preservation and Restoration of $58 to $60.5 million, up
6% to 10%
- Non-Orthopedic of $8 to $8.5 million, down 14% to 19%
The Company expects 2024 adjusted EBITDA1 to be towards the
lower end of the previously provided range of $25 to $30 million,
approximately 15% adjusted EBITDA1 margin, as a result of the
expected mix of OA Pain Management revenue with modestly lower US
sales offset by stronger International growth.
Conference Call and Webcast InformationAnika’s
management will hold a conference call and webcast to discuss its
financial results and business highlights today, Thursday, August
8, 2024, at 5:00 pm ET. The conference call can be accessed by
dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865
(international) and providing the conference ID number 1679035. A
live audio webcast will be available in the Investor Relations
section of Anika’s website, www.anika.com. A slide presentation
with highlights from the conference call will be available in the
Investor Relations section of the Anika website. A replay of the
webcast will be available on Anika’s website approximately two
hours after the completion of the event.
About AnikaAnika Therapeutics, Inc. (NASDAQ:
ANIK), is a global joint preservation company that creates and
delivers meaningful advancements in early intervention orthopedic
care. Leveraging our core expertise in hyaluronic acid and implant
solutions, we partner with clinicians to provide minimally invasive
products that restore active living for people around the world.
Our focus is on high opportunity spaces within orthopedics,
including Osteoarthritis Pain Management, Regenerative Solutions,
Sports Medicine and Arthrosurface Joint Solutions, and our products
are efficiently delivered in key sites of care, including
ambulatory surgery centers. Anika’s global operations are
headquartered outside of Boston, Massachusetts. For more
information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY,
MONOVISC, ORTHOVISC, and the Anika logo are trademarks of Anika
Therapeutics, Inc. or its subsidiaries or are licensed to Anika
Therapeutics, Inc. for its use.
Non-GAAP Financial InformationNon-GAAP
financial measures should be considered supplemental to, and not a
substitute for, the Company’s reported financial results prepared
in accordance with GAAP. Furthermore, the Company’s definition of
non-GAAP measures may differ from similarly titled measures used by
others. Because non-GAAP financial measures exclude the effect of
items that will increase or decrease the Company’s reported results
of operations, Anika strongly encourages investors to review the
Company’s consolidated financial statements and publicly filed
reports in their entirety. The Company presents these non-GAAP
financial measures because it uses them as supplemental measures in
internally assessing the Company’s operating performance, and, in
the case of Adjusted EBITDA, it is set as a key performance metric
to determine executive compensation. The Company also recognizes
that these non-GAAP measures are commonly used in determining
business performance more broadly and believes that they are
helpful to investors, securities analysts, and other interested
parties as a measure of comparative operating performance from
period to period.
Adjusted Gross MarginAdjusted gross margin is defined by the
Company as adjusted gross profit divided by total revenue. The
Company defines adjusted gross profit as GAAP gross profit
excluding amortization of certain acquired assets and non-cash
product rationalization charges.
Adjusted EBITDA Adjusted EBITDA is defined by the Company as
GAAP net income (loss) excluding depreciation and amortization,
interest and other income (expense), income taxes, stock-based
compensation expense, acquisition related expenses, non-cash
charges related to goodwill impairment, non-cash product
rationalization charges, severance costs and shareholder activism
costs.
Adjusted Net Income (Loss) and Adjusted EPS Adjusted net income
(loss) is defined by the Company as GAAP net income excluding
acquisition related expenses, inclusive of the impact of purchase
accounting, on a tax effected basis, non-cash charges related to
goodwill impairment, non-cash product rationalization charges,
stock-based compensation and charges related to discontinuation of
a software project. Adjusted diluted EPS is defined by the Company
as GAAP diluted EPS excluding acquisition related expenses and the
impact of purchase accounting, each on a tax-adjusted per share
basis, non-cash product rationalization charges, stock-based
compensation, severance costs and shareholder activism costs.
Beginning in the first quarter of 2024, adjusted net income (loss)
and adjusted EPS were revised to exclude stock-based compensation,
net of tax, and this revised calculation is reflected for all
periods presented.
A reconciliation of adjusted gross profit to gross profit (and
the associated adjusted gross margin calculation), adjusted EBITDA
to net income (loss), adjusted net income (loss) to net income
(loss) and adjusted diluted EPS to diluted EPS, the most directly
comparable financial measures calculated and presented in
accordance with GAAP, is shown in the tables at the end of this
release.
Forward-Looking Statements This press release
may contain forward-looking statements, within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, concerning
the Company's expectations, anticipations, intentions, beliefs or
strategies regarding the future which are not statements of
historical fact, including statements in Dr. Blanchard’s quote and
in the section titled Strategic Updates about the potential impact
of Integrity in the market, the timing of the regulatory pathway
and launch of Hyalofast and the US approval of Cingal, and in the
section titled Fiscal 2024 Guidance. These statements are based
upon the current beliefs and expectations of the Company's
management and are subject to significant risks, uncertainties, and
other factors. The Company's actual results could differ materially
from any anticipated future results, performance, or achievements
described in the forward-looking statements as a result of a number
of factors including, but not limited to, (i) the Company's ability
to successfully commence and/or complete clinical trials of its
products on a timely basis or at all; (ii) the Company's ability to
obtain pre-clinical or clinical data to support domestic and
international pre-market approval applications, 510(k)
applications, or new drug applications, or to timely file and
receive FDA or other regulatory approvals or clearances of its
products; (iii) that such approvals will not be obtained in a
timely manner or without the need for additional clinical trials,
other testing or regulatory submissions, as applicable; (iv) the
Company's research and product development efforts and their
relative success, including whether we have any meaningful sales of
any new products resulting from such efforts; (v) the cost
effectiveness and efficiency of the Company's clinical studies,
manufacturing operations, and production planning; (vi) the
strength of the economies in which the Company operates or will be
operating, as well as the political stability of any of those
geographic areas; (vii) future determinations by the Company to
allocate resources to products and in directions not presently
contemplated; (viii) the Company's ability to successfully
commercialize its products, in the U.S. and abroad; (ix)
the Company's ability to provide an adequate and timely supply of
its products to its customers; and (x) the Company's ability to
achieve its growth targets. Additional factors and risks are
described in the Company's periodic reports filed with
the Securities and Exchange Commission, and they are available
on the SEC's website
at www.sec.gov. Forward-looking statements
are made based on information available to the Company on the date
of this press release, and the Company assumes no obligation to
update the information contained in this press release.
For Investor Inquiries:Anika Therapeutics,
Inc.Mark Namaroff, 781-457-9287Vice President, Investor Relations,
ESG and Corporate Communicationsinvestorrelations@anika.com
Anika
Therapeutics, Inc. and Subsidiaries |
Consolidated
Statements of Operations |
(in
thousands, except per share data) |
(unaudited) |
|
|
|
|
|
|
|
|
|
For the
Three Months Ended June 30, |
|
For the Six
Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenue |
$ |
41,921 |
|
|
$ |
44,302 |
|
|
$ |
82,444 |
|
|
$ |
82,226 |
|
Cost of Revenue |
|
14,556 |
|
|
|
15,330 |
|
|
|
30,451 |
|
|
|
30,411 |
|
Gross Profit |
|
27,365 |
|
|
|
28,972 |
|
|
|
51,993 |
|
|
|
51,815 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Research and development |
|
7,398 |
|
|
|
8,914 |
|
|
|
15,562 |
|
|
|
17,314 |
|
Selling, general and administrative |
|
19,806 |
|
|
|
23,689 |
|
|
|
41,333 |
|
|
|
50,685 |
|
Total operating expenses |
|
27,204 |
|
|
|
32,603 |
|
|
|
56,895 |
|
|
|
67,999 |
|
Income (loss) from operations |
|
161 |
|
|
|
(3,631 |
) |
|
|
(4,902 |
) |
|
|
(16,184 |
) |
Interest and other income (expense), net |
|
595 |
|
|
|
561 |
|
|
|
1,187 |
|
|
|
1,100 |
|
Income (loss) before income taxes |
|
756 |
|
|
|
(3,070 |
) |
|
|
(3,715 |
) |
|
|
(15,084 |
) |
Provision for (benefit from) income taxes |
|
844 |
|
|
|
(329 |
) |
|
|
887 |
|
|
|
(1,993 |
) |
Net loss |
$ |
(88 |
) |
|
$ |
(2,741 |
) |
|
$ |
(4,602 |
) |
|
$ |
(13,091 |
) |
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
Basic |
$ |
(0.01 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.31 |
) |
|
$ |
(0.89 |
) |
Diluted |
$ |
(0.01 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.31 |
) |
|
$ |
(0.89 |
) |
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
Basic |
|
14,839 |
|
|
|
14,688 |
|
|
|
14,769 |
|
|
|
14,671 |
|
Diluted |
|
14,839 |
|
|
|
14,688 |
|
|
|
14,769 |
|
|
|
14,671 |
|
Anika
Therapeutics, Inc. and Subsidiaries |
Consolidated
Balance Sheets |
(in
thousands, except per share data) |
(unaudited) |
|
|
|
|
|
June
30, |
|
December
31, |
ASSETS |
|
2024 |
|
|
|
2023 |
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
62,822 |
|
|
$ |
72,867 |
|
Accounts receivable, net |
|
33,773 |
|
|
|
35,961 |
|
Inventories, net |
|
51,464 |
|
|
|
46,386 |
|
Prepaid expenses and other current assets |
|
6,941 |
|
|
|
8,095 |
|
Total current assets |
|
155,000 |
|
|
|
163,309 |
|
Property and equipment, net |
|
47,685 |
|
|
|
46,198 |
|
Right-of-use assets |
|
27,765 |
|
|
|
28,767 |
|
Other long-term assets |
|
19,524 |
|
|
|
18,672 |
|
Deferred tax assets |
|
1,362 |
|
|
|
1,489 |
|
Intangible assets, net |
|
3,969 |
|
|
|
4,626 |
|
Goodwill |
|
7,350 |
|
|
|
7,571 |
|
Total assets |
$ |
262,655 |
|
|
$ |
270,632 |
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
9,994 |
|
|
$ |
9,860 |
|
Accrued expenses and other current liabilities |
|
16,127 |
|
|
|
21,199 |
|
Total current liabilities |
|
26,121 |
|
|
|
31,059 |
|
Other long-term liabilities |
|
407 |
|
|
|
404 |
|
Lease liabilities |
|
25,789 |
|
|
|
26,904 |
|
|
|
|
|
Stockholders’ equity: |
|
|
|
Common stock, $0.01 par value |
|
148 |
|
|
|
147 |
|
Additional paid-in-capital |
|
93,156 |
|
|
|
90,009 |
|
Accumulated other comprehensive loss |
|
(6,416 |
) |
|
|
(5,943 |
) |
Retained earnings |
|
123,450 |
|
|
|
128,052 |
|
Total stockholders’ equity |
|
210,338 |
|
|
|
212,265 |
|
Total liabilities and stockholders’ equity |
$ |
262,655 |
|
|
$ |
270,632 |
|
Anika
Therapeutics, Inc. and Subsidiaries |
Reconciliation of GAAP Gross Profit to Adjusted Gross
Profit |
(in
thousands) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the
Three Months Ended June 30, |
|
For the Six
Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Gross Profit |
$ |
27,365 |
|
|
$ |
28,972 |
|
|
$ |
51,993 |
|
|
$ |
51,815 |
|
Product rationalization related charges |
|
- |
|
|
|
- |
|
|
|
472 |
|
|
|
- |
|
Acquisition related intangible asset amortization |
|
154 |
|
|
|
1,561 |
|
|
|
311 |
|
|
|
3,123 |
|
Adjusted Gross Profit |
$ |
27,519 |
|
|
$ |
30,533 |
|
|
$ |
52,776 |
|
|
$ |
54,938 |
|
|
|
|
|
|
|
|
|
Unadjusted Gross Margin |
|
65 |
% |
|
|
65 |
% |
|
|
63 |
% |
|
|
63 |
% |
Adjusted Gross Margin |
|
66 |
% |
|
|
69 |
% |
|
|
64 |
% |
|
|
67 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anika
Therapeutics, Inc. and Subsidiaries |
Reconciliation of GAAP Net Income to Adjusted
EBITDA |
(in
thousands) |
(unaudited) |
|
|
|
|
|
|
|
|
|
For the
Three Months Ended June 30, |
|
For the Six
Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net loss |
$ |
(88 |
) |
|
$ |
(2,741 |
) |
|
$ |
(4,602 |
) |
|
$ |
(13,091 |
) |
Interest and other (income) expense, net |
|
(595 |
) |
|
|
(561 |
) |
|
|
(1,187 |
) |
|
|
(1,100 |
) |
Provision for (benefit from) income taxes |
|
844 |
|
|
|
(329 |
) |
|
|
887 |
|
|
|
(1,993 |
) |
Depreciation and amortization |
|
1,889 |
|
|
|
1,764 |
|
|
|
3,755 |
|
|
|
3,528 |
|
Stock-based compensation |
|
3,891 |
|
|
|
4,150 |
|
|
|
7,481 |
|
|
|
7,867 |
|
Product rationalization |
|
- |
|
|
|
- |
|
|
|
472 |
|
|
|
- |
|
Arbitration settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
3,250 |
|
Acquisition related intangible asset amortization |
|
169 |
|
|
|
1,787 |
|
|
|
366 |
|
|
|
3,574 |
|
Discontinuation of software development project |
|
(1,404 |
) |
|
|
- |
|
|
|
(1,404 |
) |
|
|
- |
|
Severance costs |
|
- |
|
|
|
- |
|
|
|
839 |
|
|
|
- |
|
Costs of shareholder activism |
|
1,584 |
|
|
|
2,202 |
|
|
|
2,185 |
|
|
|
3,033 |
|
Adjusted EBITDA |
$ |
6,290 |
|
|
$ |
6,272 |
|
|
$ |
8,792 |
|
|
$ |
5,068 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anika
Therapeutics, Inc. and Subsidiaries |
Reconciliation of GAAP Net Income to Adjusted Net
Income |
(in
thousands) |
(unaudited) |
|
|
|
|
|
|
|
|
|
For the
Three Months Ended June 30, |
|
For the Six
Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net loss |
$ |
(88 |
) |
|
$ |
(2,741 |
) |
|
$ |
(4,602 |
) |
|
$ |
(13,091 |
) |
Product rationalization, tax effected |
|
- |
|
|
|
- |
|
|
|
514 |
|
|
|
- |
|
Arbitration settlement, tax effected |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,800 |
|
Share-based compensation, tax effected |
|
2,393 |
|
|
|
3,712 |
|
|
|
8,154 |
|
|
|
6,779 |
|
Acquisition related intangible asset amortization, tax
effected |
|
103 |
|
|
|
1,598 |
|
|
|
398 |
|
|
|
3,080 |
|
Discontinuation of software development project, tax effected |
|
(864 |
) |
|
|
- |
|
|
|
(1,530 |
) |
|
|
- |
|
Severance costs, tax effected |
|
- |
|
|
|
- |
|
|
|
914 |
|
|
|
- |
|
Costs of shareholder activism, tax effected |
|
975 |
|
|
|
1,970 |
|
|
|
2,381 |
|
|
|
2,613 |
|
Adjusted net income |
$ |
2,519 |
|
|
$ |
4,539 |
|
|
$ |
6,229 |
|
|
$ |
2,181 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anika
Therapeutics, Inc. and Subsidiaries |
Reconciliation of GAAP Diluted Earnings Per Share to
Adjusted Diluted Earnings Per Share |
(in
thousands, except per share data) |
(unaudited) |
|
|
|
|
|
|
|
|
|
For the
Three Months Ended June 30, |
|
For the Six
Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Diluted net loss per share |
$ |
(0.01 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.31 |
) |
|
$ |
(0.89 |
) |
Product rationalization, tax effected |
|
- |
|
|
|
- |
|
|
|
0.03 |
|
|
|
- |
|
Arbitration settlement, tax effected |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
0.19 |
|
Share-based compensation, tax effected |
|
0.16 |
|
|
|
0.25 |
|
|
|
0.55 |
|
|
|
0.46 |
|
Acquisition related intangible asset amortization, tax
effected |
|
0.01 |
|
|
|
0.11 |
|
|
|
0.03 |
|
|
|
0.21 |
|
Discontinuation of software development project, tax effected |
|
(0.06 |
) |
|
|
- |
|
|
|
(0.10 |
) |
|
|
- |
|
Severance costs, tax effected |
|
- |
|
|
|
- |
|
|
|
0.06 |
|
|
|
- |
|
Costs of shareholder activism, tax effected |
|
0.07 |
|
|
|
0.14 |
|
|
|
0.16 |
|
|
|
0.18 |
|
Adjusted diluted net income per share |
$ |
0.17 |
|
|
$ |
0.31 |
|
|
$ |
0.42 |
|
|
$ |
0.15 |
|
Anika
Therapeutics, Inc. and Subsidiaries |
Revenue by
Product Family |
(in
thousands, except percentages) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the
Three Months Ended June 30, |
|
For the Six
Months Ended June 30, |
|
|
2024 |
|
|
|
2023 |
|
|
$ change |
|
% change |
|
|
2024 |
|
|
|
2023 |
|
|
$ change |
% change |
OA Pain Management |
$ |
26,658 |
|
|
$ |
29,334 |
|
|
$ |
(2,676 |
) |
|
|
-9 |
% |
|
$ |
50,976 |
|
|
$ |
51,967 |
|
|
$ |
(991 |
) |
|
|
-2 |
% |
Joint Preservation and Restoration |
|
13,554 |
|
|
|
12,660 |
|
|
|
894 |
|
|
|
7 |
% |
|
|
27,395 |
|
|
|
26,113 |
|
|
|
1,282 |
|
|
|
5 |
% |
Non-Orthopedic |
|
1,709 |
|
|
|
2,308 |
|
|
|
(599 |
) |
|
|
-26 |
% |
|
|
4,073 |
|
|
|
4,146 |
|
|
|
(73 |
) |
|
|
-2 |
% |
Revenue |
$ |
41,921 |
|
|
$ |
44,302 |
|
|
$ |
(2,381 |
) |
|
|
-5 |
% |
|
$ |
82,444 |
|
|
$ |
82,226 |
|
|
$ |
218 |
|
|
|
0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anika Therapeutics (NASDAQ:ANIK)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Anika Therapeutics (NASDAQ:ANIK)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024